BELL-ID
Bell ID, the mobile payments specialist recently acquired by Rambus Cryptography Research, today announces it will support international issuing banks, payment schemes and processors to integrate with Android Pay. Bell ID customers can utilize its Token Service Provider (TSP) software to enable and secure near field communication (NFC) payments functionality on Android phones.
Android Pay is a mobile payment solution that offers people simplicity and security when paying for things with their Android devices. Bell ID’s TSP technology will secure Android Pay transactions via tokenization*.
"Mobile payments is a big priority for Google and we're working to support a wide range of issuers to make Android Pay available to everyone," says Pali Bhat, Senior Director, Product Management, Google, "Bell ID's integration takes us one step further in this direction.”
“A lot of our customers are keen to integrate with Android Pay and this support enables us to answer this demand,” adds Dr. Martin Scott, senior vice president and general manager of the Rambus Cryptography Research division. “With this relationship in place, Bell ID is now one of the few solution providers that can help banks to reach their full customer base, regardless of the smartphone they own. Bell ID does this by supporting the vast majority of OEM wallet, mobile operating system and secure element combinations. 2016 is going to be the biggest year yet and we're excited to be supporting the future of payments.”
Bell ID offers one software platform for issuing banks, processors and payment schemes to support mobile NFC payments. EMV® card credentials can be loaded and managed on a mobile device or in the cloud, using host card emulation (HCE). The solution is backed by a comprehensive EMVCo tokenization module that removes vulnerable card data from the payment network.
Visit the Bell ID website to learn more about Token Service Provider or Android Pay integration. Bell ID will also be present at Mobile World Congress with its virtual reality demonstration of the tokenization process associated with a mobile payment http://www.bellid.com/company/events/ .
For further media information, please contact Rob Peryer or David Amos at iseepr: rob@iseepr.co.uk / david@iseepr.co.uk or on + 44 (0) 1943 468007
Notes to editors
* Tokenization secures your payment credentials by replacing them with a randomly generated number which resembles the customer’s primary account number (PAN). This unique identifier, called a ‘payment token’ or ‘tokenized PAN’, is worthless if stolen as it essentially acts as a reference for a consumer’s original card data which only the card networks and/or the consumer’s bank can map back to the original account.
About Bell ID
Banks, governments and enterprises worldwide rely on Bell ID solutions to safely issue and manage credentials on many millions of smartcards, smartphones and connected devices. The Bell ID software solutions integrate with any third party technology and simplify the issuing complexities of payment, identity, loyalty and transit applications. Whether it’s EMV payments data stored on a chip card, in an NFC-enabled mobile device or in the cloud leveraging HCE, Bell ID has the expertise to manage the lifecycle of any application on any form factor. These award winning solutions meet the demanding requirements of international standardization bodies and payment networks.
In January 2016, Bell ID was acquired by Rambus (NASDAQ:RMBS) Cryptography Research and has a strong presence across the globe with operations in Europe, North America, Australia, the Middle East and Africa. Bell ID maintains one of the largest teams worldwide dedicated to credential lifecycle management.
For more information, please visit www.bellid.com or follow us on LinkedIn and Twitter .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160217006638/en/
Contact:
iseepr
Rob Peryer, + 44 (0) 1943 468007
rob@iseepr.co.uk
David
Amos, + 44 (0) 1943 468007
david@iseepr.co.uk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom